focus -WSS

focus

author：comprehensive 2025-10-01 18:45:45 - browse：252

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Radiology is caught between AI's potential and concern for patients

WSS

How to protect coverage of PrEP

Spinal cord stimulation reduces pain in amputees, study finds

What Henrietta Lacks's story taught me about my role as a doctor

My chronic pain journey would have been easier knowing 5 things % STAT

In diabetes hearing, Sanders takes on a new foe: food makers

Transgender women dream of pregnancy via uterus transplants

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

4 missing after record

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

At least 13 dead in Texas as scorching temps continue

My chronic pain journey would have been easier knowing 5 things % STAT

Drug repurposing or repositioning? The language matters

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

How to save PrEP access — and even expand it

Statins reduce cardiovascular risk in people living with HIV

Wikipedia

4 missing after record

Pfizer plans to depart BIO

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Spinal cord stimulation reduces pain in amputees, study finds

Inside the culture of fear in the White House science office of Eric Lander

knowledge

hotspot

focus

knowledge